"Expert Discusses Promising Findings With Imetelstat in Advanced Myelofibrosis" - Danielle Ternyila
Ruxolitinib (Jakafi) is currently the only FDA-approved treatment option for patients with myelofibrosis (MF). For patients who relapse on or are refractory to this drug, there are limited options available. Researchers at the Icahn School of Medicine at Mount Sinai have found promising results using imetelstat, a telomerase inhibitor. John O. Mascarenhas, MD, associate professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai said, “Imetelstat is a small molecular inhibitor on the enzyme telomerase that actually targets chromosomes and has been shown to be upregulated in malignancies in general, but specifically in MF. It’s a therapeutic target.”
— John O. Mascarenhas, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai